



Supplementary Figure 5: Comparison of RRAS and measurements of tumor size and number. ROC curve analysis was used to assess the performance of the RRAS in predicting post-transplant HCC recurrence when compared to measurement of tumor size and number on both imaging and explant pathology (radiographic measurements (dotted line, AUC=0.535), gross measurements (dashed line, AUC=0.597), RRAS criteria (solid line, AUC=0.836), n=184). Explants were stratified by whether they meet or exceed Milan/UCSF criteria, and there was no significant difference in outcome when comparing criteria assignment using either radiographic or gross tumor measurements ($p=0.284$). However, RRAS methods allowed for a more accurate prediction of tumor recurrence than both radiographic and gross assignment to Milan/UCSF categories ($p<0.0001$).